Ozempic is usually talked about because of what it does to blood sugar and weight. But that is only part of the story.
Semaglutide has now been studied in thousands of people with cardiovascular disease, and the results suggest it can reduce the risk of heart attack and stroke in some groups.
That raises a bigger question.
If Ozempic is not a heart drug, why does it seem to help the heart?
The answer is not as simple as “because people lose weight.”
Newer research suggests semaglutide may be affecting several parts of cardiovascular health at once, from blood pressure and inflammation to what happens inside the smallest blood vessels of the heart.
But the benefit is not the same for everyone, and the evidence depends heavily on who was studied, which dose they took, and what their cardiovascular risk looked like before treatment began.
So, is Ozempic good for your heart?
For some people, yes.
In brief
Here is what the trials actually show, how semaglutide may be helping, and what those findings mean for understanding your own cardiovascular health.
Ozempic is a brand name. Semaglutide is the drug inside it.
Semaglutide belongs to a group of medicines called GLP-1 receptor agonists. GLP-1 is a hormone your body naturally releases after you eat, and it plays a role in controlling blood sugar and appetite.
Semaglutide works by activating the same GLP-1 receptors.
When blood sugar is high, it helps the pancreas release more insulin and reduces the release of glucagon, a hormone that raises blood sugar. It also acts on areas of the brain involved in appetite, helping people feel fuller and reducing hunger and food intake. It can also slow gastric emptying, particularly after eating.
That is why Ozempic was developed and approved as a treatment for type 2 diabetes.
But Ozempic is not the only medicine that contains semaglutide.
Wegovy contains the same active drug, but it has different approved uses and dosing. It is primarily used for weight management in people who meet specific criteria, and cardiovascular outcome research has also led to cardiovascular risk-reduction indications in certain populations.
When people ask whether “Ozempic is good for your heart,” much of the research they are referring to is actually on semaglutide. Some trials used doses associated with Ozempic, while others used the higher-dose semaglutide regimen associated with Wegovy.
And semaglutide may be doing more than changing blood sugar or body weight.
Clinical studies have also found changes in systolic blood pressure, blood lipids and inflammation. Researchers are now investigating whether there may be more direct effects on the cardiovascular system too.
That brings us to the bigger question: does semaglutide actually reduce heart attacks and strokes?
Yes. In certain groups of people at high cardiovascular risk, semaglutide has been shown to reduce the risk of heart attack, stroke, and cardiovascular death.
The clearest evidence comes from a large study. Researchers followed 17,604 adults who already had cardiovascular disease and were living with overweight or obesity, but did not have diabetes.
Over an average of around 40 months, a major cardiovascular event, cardiovascular death, a non-fatal heart attack or a non-fatal stroke occurred in 6.5% of people taking semaglutide, compared with 8.0% taking placebo.
That works out to a 20% lower relative risk.
There is an important detail here, though.
SELECT did not test the standard doses typically associated with Ozempic. It used 2.4 mg of semaglutide once a week, the dose used with Wegovy.
So what about semaglutide at Ozempic doses?
We have evidence there too.
The earlier SUSTAIN-6 trial studied 3,297 people with type 2 diabetes who were at high cardiovascular risk. Participants received either 0.5 mg or 1.0 mg of semaglutide once a week.
Major cardiovascular events occurred in 6.6% of people taking semaglutide compared with 8.9% taking placebo. You may see this reported as a 26% lower relative risk.
But there is some context behind that number.
SUSTAIN-6 was originally designed to establish that semaglutide did not increase cardiovascular risk compared with placebo. In other words, its primary statistical aim was cardiovascular safety rather than proving that semaglutide was better at preventing cardiovascular events.
The result was encouraging, but researchers needed larger studies to understand whether the cardiovascular benefit was real.
Those studies followed.
More recently, the SOUL trial looked at a different form again: oral semaglutide. It included 9,650 people with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both.
A major cardiovascular event occurred in 12.0% of people taking oral semaglutide compared with 13.8% taking placebo, corresponding to a 14% lower relative risk.
The cardiovascular findings are no longer coming from one trial, one dose, or even one form of semaglutide.
But there is an equally important limitation.
These studies did not take a group of otherwise healthy people, give half of them Ozempic, and find out whether it prevented their first heart attack.
The people in these trials already had cardiovascular disease, type 2 diabetes, chronic kidney disease, or other features that put them at higher cardiovascular risk.
So semaglutide has good evidence for reducing cardiovascular events in specific higher-risk groups.
That does not mean everyone taking Ozempic receives the same heart protection.
And it leaves us with an interesting question: why would a medicine developed around diabetes and weight have an effect on the heart in the first place?
For a long time, the cardiovascular results were easier to see than to explain.
People taking semaglutide were having fewer heart attacks and strokes. But was that simply because they were losing weight, lowering their blood sugar and improving their blood pressure?
Probably not entirely.
Semaglutide appears to affect several things that matter for cardiovascular health at the same time, including blood pressure, glucose regulation, inflammation and some blood lipids.
And in February 2026, researchers from the University of Bristol and UCL published another possible piece of the puzzle. Nature Communications study on GLP-1 and coronary blood flow
Imagine someone has a heart attack because one of the arteries supplying their heart becomes blocked.
Doctors reopen the artery and restore blood flow.
You would expect the problem to be solved.
But that does not always happen.
In some people, the main artery is open again while blood still struggles to reach parts of the heart muscle through the much smaller vessels downstream. This is known as “no-reflow”, and the researchers note that it can affect up to half of patients after a blocked coronary artery is reopened.
That matters because no-reflow is associated with a larger area of damaged heart muscle, poorer heart function and worse outcomes after a heart attack.
The researchers looked at tiny cells called pericytes, which sit around the capillaries supplying the heart.
During a period of reduced oxygen, these cells can contract and squeeze the capillaries around them. Even when the main artery is reopened, those smaller vessels can remain narrowed.
Here is where GLP-1 becomes interesting.
In animal and isolated-heart experiments, activating GLP-1 receptors helped the pericytes relax. It did this through potassium channels known as KATP channels, allowing the capillaries to widen and blood flow to improve.
When those channels were blocked or genetically removed, the protective effect disappeared.
It gives researchers a plausible mechanism for how GLP-1 signalling could act more directly on blood flow within the heart, rather than helping only through weight loss or better blood sugar control.
But there is an important limit to what we can say.
This study was conducted using animal models, isolated heart tissue and cultured cells. It did not show that taking Ozempic prevents no-reflow in people after a heart attack.
So this is not yet a clinical explanation for all of the cardiovascular benefit seen in semaglutide trials.
It is, however, an important clue.
And it makes the next question even more interesting: if semaglutide protects the heart, how much of that benefit actually comes from losing weight?
You might assume the heart benefit comes down to one thing: people lose weight, so their cardiovascular risk improves.
The evidence suggests it is not that simple.
Researchers went back through the SELECT trial and looked at whether cardiovascular benefit depended on how much body fat someone had at the start, or how much weight they lost after beginning semaglutide.
It did not.
People appeared to receive cardiovascular benefit across different starting body sizes, and the amount of early weight loss did not clearly predict how much protection they received from major cardiovascular events.
That matters because it suggests weight loss is only part of the explanation.
Semaglutide also affects blood pressure, glucose regulation, inflammation and blood lipids, all of which can influence cardiovascular risk. And, as the newer mechanistic research suggests, there may also be effects occurring directly within the cardiovascular system.
The authors of the SELECT analysis argued that semaglutide should be thought of as more than a weight-loss treatment in people with established cardiovascular disease.
Absolutely. Here is the same section with em dashes removed.
If semaglutide is doing more than helping people lose weight, you would expect to see that somewhere else in the body.
And you do.
A 2026 analysis of the SOUL trial looked at how several cardiovascular risk factors changed in people taking oral semaglutide. Some of the changes appeared surprisingly early.
By 13 weeks, people taking semaglutide had seen reductions in:
The timing is interesting.
Blood sugar, blood pressure and inflammation were already moving within the first few months, while weight loss continued more gradually and reached its greatest reduction later.
That is another clue that the cardiovascular effects of semaglutide may not depend on weight loss alone. The cholesterol results are also more nuanced than simply saying semaglutide “lowers cholesterol.”
LDL cholesterol was lower with semaglutide at 13 weeks, but that difference was no longer significant by week 156.
Other measures, including non-HDL cholesterol and triglycerides, showed more sustained differences over time.Then there is inflammation.
High-sensitivity C-reactive protein, or hs-CRP, is a blood test used to measure low-grade inflammation. In SOUL, hs-CRP fell by around 18% by week 13, and the reduction was still present later in the trial.
This finding matters because cardiovascular health is not captured by one number.
LDL cholesterol is important, but it sits alongside blood pressure, glucose regulation, triglycerides, inflammation and other measures of cardiovascular and metabolic health.
So if you are trying to understand what semaglutide is changing in your body, looking only at your weight or only at one cholesterol result can miss a much bigger part of the picture.
Next we can move into “Can Ozempic cause heart problems?”
If semaglutide protects the heart, it is fair to ask the opposite question.
There is one effect worth knowing about.
Semaglutide raises your resting heart rate, by roughly 2 to 4 beats per minute. The same pattern shows up across other GLP-1 medicines, so researchers treat it as a class effect rather than something specific to Ozempic.
It tends to appear while the dose is being increased, and it does not reliably settle back down.
Most people never notice it. Two to four beats per minute is not something you feel. Some people do see a larger rise, and a resting pulse that sits persistently high is worth raising with your clinician.
The obvious worry was whether a faster heart rate might trigger abnormal heart rhythms.
So far the evidence does not support that. Pooled data from dozens of randomised trials, covering nearly 80,000 people, found no increase in atrial fibrillation, ventricular arrhythmias or sudden cardiac death.
In both SELECT and SOUL, serious adverse events were slightly less common in the semaglutide groups than in the placebo groups.
The more practical risk is dehydration
Around 1 to 2% of people in trials report palpitations, usually in the first weeks.
In most cases the cause is not the drug acting on the heart. It is dehydration and electrolyte imbalance from the gastrointestinal side effects.
Nausea, vomiting and diarrhoea are the most common reasons people stop taking semaglutide. In SELECT, gastrointestinal side effects led 10% of the semaglutide group to discontinue, compared with 2% on placebo.
If you are losing fluid and not replacing it, your heart rate rises, your electrolytes shift and your kidneys take the strain. That is a far more likely route to feeling unwell than anything happening in the heart muscle.
What else showed up in the trials
Two findings outside the cardiovascular system are worth knowing.
SUSTAIN-6 recorded more diabetic retinopathy complications in the semaglutide group, 3.0% compared with 1.8%. SOUL recorded slightly more neoplasms, 6.8% compared with 5.7%.
Semaglutide also lowers blood pressure, so the effect stacks with blood pressure medication.
The honest limitation
Every trial in this article ran for around four years, in people who already had cardiovascular disease, diabetes or kidney disease.
That tells us a lot about semaglutide in higher-risk groups over a few years. It tells us much less about a healthy person taking it for a decade.
That is not a reason to avoid it. It is a reason to know your numbers before you start, and to keep watching them.
There is no single “Ozempic blood test” that everyone needs.
What you monitor depends on why you are taking semaglutide, your existing health conditions and what your clinician is already tracking.
If you are taking Ozempic for type 2 diabetes, HbA1c is one of the main measurements to follow. It shows your average blood sugar over the previous two to three months and helps show whether treatment is actually improving glucose control. Current diabetes guidelines recommend checking HbA1c at least twice a year when treatment is stable, and more often when treatment has recently changed or targets are not being met. American Diabetes Association Standards of Care 2026
But blood sugar is only part of the picture.
Depending on your health history, it can also be useful to follow:
For people with obesity, current guidance also includes measures such as HbA1c, lipid profile, blood pressure and heart rate when assessing metabolic and cardiovascular health. ADA Standards of Care in Overweight and Obesity 2026
The point is not to order every possible test because you are taking Ozempic.
It is to know what you looked like before treatment, what is changing while you are on it, and whether those changes are moving in the direction you expected.
That is where broader testing can become useful.
But if you want to understand what is changing inside your body, the scale is only one place to look.
At Axo Longevity we run 100+ lab tests across 36+ health areas and read each result against that wider picture rather than as an isolated number.
You receive:
- Your Axo Longevity Health Score, showing how your key systems are performing together
- Results interpreted against optimal ranges, not only laboratory thresholds
- A personalized action plan shaped around your results, lifestyle, and goals
- Repeat testing so you can see what is changing over time.
This article is for educational purposes only and does not replace medical advice, diagnosis or treatment. Consult a qualified healthcare professional for personalised care.
